0000-0003-2931-3652 About
Dr Alfonso Urbanucci graduated from the University of Perugia, in Italy, and got his PhD in cancer genetics and molecular biology of cancer in Finland, at the University of Tampere, in 2012.
Currently, Dr Alfonso Urbanucci is a Senior Research Fellow of the Tampere Institute of Advanced Study. He is the group leader of the “Genomic Regulation for Precision Cancer Medicine Lab” within the Prostate Cancer Research Center at the Faculty of Medicine and Health Technology. He is also a project group leader and principal investigator at the Department of Tumor Biology, Institute for Cancer Research within the Oslo University Hospital, and Associate Investigator of the Norwegian Center for Molecular Medicine (EMBL partnership).
Dr Urbanucci researches prostate cancer using models and clinical specimens to understand the role of the prostate tumor immune microenvironment and of immune cells in shaping tumor behavior. Further, the goal of the research is to promote the use of transcriptional signatures derived from studies of single cells as a footprint for characterizing the tumor ability to relapse and inform clinical decision making in prostate cancer patients.
Employment
-
Tampere University Group Leader2022 - Present
-
Oslo Universitetssykehus Principal Investigator, Project Group Leader2018 - Present
-
Tampere University
Education
-
Oslo Universitetssykehus
Projects & Funding
Projects & funding information is unavailable.
Publications (74)
- Happening in the Prostate Tumor Microenvironment Save
- AR suppression rewires a SOX4 regulatory program to promote enzalutamide resistance in prostate cancer Save
- Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer Save
- Patient‐derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways Save
- Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironment Save
- Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers Save
- Combination of PSMA targeting alpha-emitting radioligand [212Pb]Pb-AB001 with BET bromodomain inhibitors in in vitro prostate cancer models Save
- Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer Save
- Link between circadian rhythm and benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) Save
- Supplementary Figure 3 from The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells Save